All In Biotech

Drug Trial Radar · NCT00070278

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Jan 2005

Primary completion

Sep 2007

Sponsor

Lead sponsor
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. It is not yet known which combination chemotherapy regimen is more effective in treating early breast cancer. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating women who are undergoing surgery for early invasive breast cancer.

Conditions

  • Breast Cancer

Interventions

  • cyclophosphamideDrug

  • epirubicin hydrochlorideDrug

  • gemcitabine hydrochlorideDrug

  • paclitaxelDrug

  • comparative genomic hybridizationGenetic

  • microarray analysisGenetic

  • mutation analysisGenetic

  • conventional surgeryProcedure

  • neoadjuvant therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete pathological response after 4 courses

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust

    Cambridge, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.